Transgene Biotek Peer Comparison

Snapshot Summary

Transgene Biotek Ltd. shows poor financial health with negative profitability metrics, high debt levels, and low valuation attractiveness. In contrast, peers like Max Healthcare and Apollo Hospitals demonstrate strong growth and profitability, making them standout options. Transgene's financial weaknesses categorize it as a high-risk investment, while companies like Aster DM Healthcare are undervalued despite low performance metrics.

• Transgene Biotek Ltd. has negative PE and ROE, indicating financial distress.
• Max Healthcare and Apollo Hospitals lead in profitability metrics and revenue growth.
• Aster DM Healthcare is a value pick with a low PE but has poor growth performance.

• Max Healthcare Institute Ltd.: Highest revenue growth YoY and strong profitability metrics including a ROE of 13.47%.
• Apollo Hospitals Enterprise Ltd.: High EPS growth and solid profitability with a PE of 85.15 and ROE of 20.51%.

Stock	CMP	Market Cap	P/E	ROE (%)	ROCE (%)	Debt/Equity
Transgene Biotek Ltd.	₹3.80	₹28.79Cr	-21.99	-5.94%	-2.10%	1.31
APOLLOHOSP	₹7,824.50	₹1,12,510.06Cr	71.50	20.51%	21.19%	0.67
MAXHEALTH	₹1,145.90	₹1,11,466.91Cr	97.13	13.47%	16.26%	0.14
FORTIS	₹1,030.70	₹77,269.97Cr	88.97	9.77%	12.14%	0.25
NH	₹1,785.00	₹36,492.71Cr	46.46	24.27%	21.62%	0.61
ASTERDM	₹678.45	₹35,159.69Cr	110.51	9.32%	11.46%	0.19
MEDANTA	₹1,274.60	₹34,290.93Cr	64.20	15.31%	20.50%	0.10

Explore

Watchlists

Command Palette

Transgene Biotek Peer Comparison

Snapshot Summary